@ShahidNShah
Evaluating digital health solutions: How to know which solutions bring value to your organization?
Watch our live event with Keynote speaker Dr. Simon Mathews, Assistant Professor of Medicine at Johns Hopkins Medicine and thought leader for improving care delivery and value through technology, as he helps shed light on this complex topic. Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.
Medigy Insights
Join us for a live event featuring Dr. Simon Mathews, an Assistant Professor of Medicine at Johns Hopkins Medicine and a thought leader in improving care delivery and value through technology. Roche, the world's largest biotech company, will host the event. Roche is a leader in research-focused healthcare, creating innovative medicines and diagnostic tests that help millions of patients globally in critical areas such as oncology, immunology, infectious diseases, ophthalmology, and neuroscience. The event promises to be an insightful experience for attendees.
Continue reading at youtube.com
Make faster decisions with community advice
- MAP Evaluation Series: An Introduction to Service Design for Community-Based Health Innovation
- Healthcare barriers through Innovation and Partnerships with Medtronics at #ETHealthLeaders Summit
- How Health Systems Can Decrease Hospital Readmissions Through Digital Health
- Shana O. Ntiri on the Benefits of Telehealth on Patient Care
- The Future of Artificial Intelligence in Healthcare
Next Article
-
Evolving Consumer Expectations Are Driving Healthcare Innovation For The Better
The rise of health tech has spurred a new generation of leaders looking to tackle the legacy industry and bring better relationships and, ultimately, better patient outcomes to the …